دورية أكاديمية
Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.
العنوان: | Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis. |
---|---|
المؤلفون: | Ho M; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Chen LJ; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Sin HPY; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Iu LPL; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Brelen M; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Ho ACH; Department of Paediatrics, Faculty of Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Lai TYY; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Young AL; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR. youngla@ha.org.hk.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR. youngla@ha.org.hk. |
المصدر: | Journal of ophthalmic inflammation and infection [J Ophthalmic Inflamm Infect] 2019 Jul 31; Vol. 9 (1), pp. 14. Date of Electronic Publication: 2019 Jul 31. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Country of Publication: Germany NLM ID: 101553216 Publication Model: Electronic Cited Medium: Print ISSN: 1869-5760 (Print) Linking ISSN: 18695760 NLM ISO Abbreviation: J Ophthalmic Inflamm Infect Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Berlin : Springer |
مستخلص: | Purpose: To report the clinical outcomes of adalimumab in treating refractory Behcet's disease (BD)-related uveitis in paediatric or adolescent patients. Methods: Retrospective review of five paediatric or adolescent patients with BD-related uveitis with a minimum follow-up of 24 months. Results: Disease quiescence was observed in 9 (90%) of 10 eyes at 12 months. The mean number of relapses per year per patient was 5 (range, 3-7) before initiation of adalimumab treatment. This was reduced to 0.2 relapse per patient per year among the five patients during the first 24 months after starting adalimumab treatment. At baseline, 5 eyes had active retinal vasculitis. Retinal vasculitis resolved in all cases (100%) after starting adalimumab. The mean time to complete resolution of inflammation was 3.4 weeks. The mean ± standard deviation logMAR best-corrected visual acuity was 0.711 ± 0.63 at baseline and improved to 0.172 ± 1.04 at 12 months (P < 0.001). None of the patients developed any adverse events associated with adalimumab treatment. Conclusion: Adalimumab was effective in preventing irreversible sight-threatening BD-related uveitis in paediatric or adolescent patients. Adalimumab appears to be a promising treatment option for young patients with recalcitrant BD-related uveitis and has a favourable safety profile. |
References: | Br J Ophthalmol. 2002 Feb;86(2):140-3. (PMID: 11815335) Mediators Inflamm. 2002 Apr;11(2):87-93. (PMID: 12061429) Am J Ophthalmol. 2003 Dec;136(6):1114-9. (PMID: 14644223) Ophthalmology. 2004 Mar;111(3):491-500; discussion 500. (PMID: 15019324) Am J Ophthalmol. 2004 Sep;138(3):373-80. (PMID: 15364218) Br J Ophthalmol. 2005 May;89(5):533-6. (PMID: 15834077) Surv Ophthalmol. 2005 Jul-Aug;50(4):297-350. (PMID: 15967189) Arthritis Rheum. 2005 Aug;52(8):2478-84. (PMID: 16052571) Am J Ophthalmol. 2005 Sep;140(3):509-16. (PMID: 16196117) Curr Opin Rheumatol. 2006 Jan;18(1):3-9. (PMID: 16344613) Ophthalmology. 2006 May;113(5):860-4.e2. (PMID: 16545455) Eye (Lond). 2007 Jun;21(6):824-5. (PMID: 16601736) J Pediatr. 2006 Oct;149(4):572-5. (PMID: 17011337) Br J Ophthalmol. 2007 Mar;91(3):319-24. (PMID: 17035274) Rheumatology (Oxford). 2007 May;46(5):736-41. (PMID: 17403712) Am J Ophthalmol. 2007 Dec;144(6):844-849. (PMID: 17953940) Rheumatology (Oxford). 2008 Mar;47(3):339-44. (PMID: 18238789) Ophthalmology. 2009 Aug;116(8):1544-51, 1551.e1. (PMID: 19651312) Rheumatol Int. 2011 Feb;31(2):243-5. (PMID: 19816689) Semin Arthritis Rheum. 2011 Aug;41(1):61-70. (PMID: 21168186) JAMA. 2011 Apr 13;305(14):1460-8. (PMID: 21486979) Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S54-7. (PMID: 21968237) Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. (PMID: 22324897) Ophthalmology. 2012 Aug;119(8):1575-81. (PMID: 22525047) Rheumatology (Oxford). 2012 Oct;51(10):1825-31. (PMID: 22723596) Br J Ophthalmol. 2013 Apr;97(4):481-6. (PMID: 23376607) Pediatr Rheumatol Online J. 2013 Apr 15;11:16. (PMID: 23587261) JAMA Ophthalmol. 2013 Nov;131(11):1405-12. (PMID: 24008391) J AAPOS. 2013 Oct;17(5):456-9. (PMID: 24160962) Ophthalmology. 2014 Mar;121(3):785-96.e3. (PMID: 24359625) Trials. 2014 Jan 09;15:14. (PMID: 24405833) Mediators Inflamm. 2013;2013:560632. (PMID: 24489444) Ophthalmic Surg Lasers Imaging Retina. 2014 Jul-Aug;45(4):332-4. (PMID: 25037015) J AAPOS. 2016 Apr;20(2):145-7. (PMID: 27079596) Int Ophthalmol. 2017 Jun;37(3):719-725. (PMID: 27432171) Ocul Immunol Inflamm. 2018;26(3):477-484. (PMID: 27775458) N Engl J Med. 2017 Apr 27;376(17):1637-1646. (PMID: 28445659) Curr Treatm Opt Rheumatol. 2017 Mar;3(1):1-16. (PMID: 28944162) Br J Ophthalmol. 2018 Dec;102(12):1672-1678. (PMID: 29459430) Ann Rheum Dis. 1984 Dec;43(6):783-9. (PMID: 6524980) J Rheumatol. 1997 Jan;24(1):128-32. (PMID: 9002023) Yonsei Med J. 1997 Dec;38(6):411-22. (PMID: 9509911) J Pediatr. 1998 Apr;132(4):721-5. (PMID: 9580778) |
فهرسة مساهمة: | Keywords: Adalimumab; Behcet’s disease; Intraocular inflammation; Retinal vasculitis; Uveitis |
تواريخ الأحداث: | Date Created: 20190802 Latest Revision: 20201001 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC6669227 |
DOI: | 10.1186/s12348-019-0181-z |
PMID: | 31367810 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1869-5760 |
---|---|
DOI: | 10.1186/s12348-019-0181-z |